TWO · 6547.TWO
Medigen Vaccine Biologics Corp.
NT$48.85-NT$0.90 (-1.81%)
Medigen Vaccine Biologics Corp.’s quoted price sits in the lower half of its reported 52-week range, 32.34% below the high.
Loading market information…
TAI · 6541.TW · TWD
Stock price, earnings
Quote as of Oct 30, 2026, 05:30 AM UTC. Cached market data; not a live quote.
One-year closing-price history · TWD. Historical prices are not a forecast.
Tanvex BioPharma, Inc.’s quoted price sits in the lower half of its reported 52-week range, 56.49% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Tanvex BioPharma, Inc.’s next earnings report is currently expected on Nov 16, 2026, with estimated earnings per share of -NT$1.52. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Tanvex BioPharma, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Tanvex BioPharma, Inc., originally known as Ruenvex Biotech, Inc., is a biopharmaceutical company founded in 2013 and based in George Town, Cayman Islands. The firm specializes in the investigation, creation, production, and sale of biosimilar medicines, with its operations spanning Taiwan and the United States. Its core mission involves developing biosimilars aimed at treating severe conditions like neutropenia, breast cancer, metastatic colorectal cancer, and psoriasis. The company's robust product portfolio includes TX01 and TX-05, both of which have successfully completed Phase III clinical trials. Additionally, TX-04 and TX-16 are currently undergoing Phase I clinical trials, while TX-52 and other potential therapies are in the pre-clinical development stage.
Latest available per-share figures in TWD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 10:33 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 | May 7, 2025 | -NT$2.09-50.86% vs estimate | NT$49.86M-75.44% vs estimate |
|---|
| Q4 2024 | Mar 14, 2025 | -NT$1.69+9.92% vs estimate | NT$2.81M-97.89% vs estimate |
|---|
| Q3 2024 | Nov 12, 2024 | -NT$1.94+11.56% vs estimate | NT$11.50M-91.35% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
NT$48.85-NT$0.90 (-1.81%)
Medigen Vaccine Biologics Corp.’s quoted price sits in the lower half of its reported 52-week range, 32.34% below the high.
NT$59.70-NT$0.10 (-0.17%)
YungShin Global Holding Corporation’s quoted price sits in the upper half of its reported 52-week range, 3.71% below the high.
NT$20.00+NT$0.10 (+0.5%)
ScinoPharm Taiwan, Ltd.’s quoted price sits in the lower half of its reported 52-week range, 31.27% below the high.
NT$150.50-NT$2.00 (-1.31%)
Ever Supreme Bio Technology Co., Ltd’s quoted price sits in the lower half of its reported 52-week range, 18.21% below the high.
NT$47.80-NT$1.20 (-2.45%)
EirGenix, Inc.’s quoted price sits in the lower half of its reported 52-week range, 43.3% below the high.
NT$72.90-NT$0.40 (-0.55%)
Excelsior Medical Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 14.84% below the high.
NT$133.50+NT$0.50 (+0.38%)
AP Biosciences Inc’s quoted price sits in the lower half of its reported 52-week range, 43.43% below the high.
NT$75.00-NT$0.80 (-1.06%)
Foresee Pharmaceuticals Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 19.96% below the high.
